These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26323186)

  • 1. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
    Targownik LE; Suissa S
    Am J Gastroenterol; 2015 Dec; 110(12):1647-50. PubMed ID: 26323186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples].
    Faillie JL; Suissa S
    Therapie; 2015; 70(3):259-63. PubMed ID: 25487848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immortal time bias and infliximab-related mortality and malignancy incidence.
    Targownik LE
    Gut; 2010 Mar; 59(3):416; author reply 416. PubMed ID: 20207649
    [No Abstract]   [Full Text] [Related]  

  • 4. Immortal time bias in pharmaco-epidemiology.
    Suissa S
    Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immortal time bias in observational studies of drug effects.
    Suissa S
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):241-9. PubMed ID: 17252614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication safety research by observational study design.
    Lao KS; Chui CS; Man KK; Lau WC; Chan EW; Wong IC
    Int J Clin Pharm; 2016 Jun; 38(3):676-84. PubMed ID: 27003827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease.
    Papamichael K; Vermeire S
    World J Gastroenterol; 2015 Apr; 21(16):4773-8. PubMed ID: 25944990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge.
    Salleron J; Danese S; D'Agay L; Peyrin-Biroulet L
    J Crohns Colitis; 2016 Sep; 10(9):1096-102. PubMed ID: 26944416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of immortal person-time when outcomes are nonfatal.
    Liang C; Seeger JD; Dore DD
    Ann Epidemiol; 2016 Mar; 26(3):212-7. PubMed ID: 26847051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.
    Liu J; Weinhandl ED; Gilbertson DT; Collins AJ; St Peter WL
    Kidney Int; 2012 Feb; 81(4):341-50. PubMed ID: 22089946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The limitations of observation studies for decision making regarding drugs efficacy and safety.
    Gueyffier F; Cucherat M
    Therapie; 2019 Apr; 74(2):181-185. PubMed ID: 30514576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the drug treatment regimens for inflammatory bowel disease.
    Brock EM; Zabihollah M
    Expert Opin Pharmacother; 1999 Nov; 1(1):15-8. PubMed ID: 11249558
    [No Abstract]   [Full Text] [Related]  

  • 14. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.
    Daniel S; Koren G; Lunenfeld E; Levy A
    Am J Obstet Gynecol; 2015 Mar; 212(3):307.e1-6. PubMed ID: 25265406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.
    Acton EK; Willis AW; Hennessy S
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):9-18. PubMed ID: 36216785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion services in the gastroenterology practice.
    Ancowitz B; Shah SA
    Gastrointest Endosc Clin N Am; 2006 Oct; 16(4):727-42. PubMed ID: 17098619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.
    Karim ME; Gustafson P; Petkau J; Tremlett H;
    Am J Epidemiol; 2016 Aug; 184(4):325-35. PubMed ID: 27455963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.
    Hernán MA; Sauer BC; Hernández-Díaz S; Platt R; Shrier I
    J Clin Epidemiol; 2016 Nov; 79():70-75. PubMed ID: 27237061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.
    Kiri VA; Pride NB; Soriano JB; Vestbo J
    Am J Respir Crit Care Med; 2005 Aug; 172(4):460-4. PubMed ID: 15901610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review.
    Iudici M; Porcher R; Riveros C; Ravaud P
    Ann Rheum Dis; 2019 Apr; 78(4):562-569. PubMed ID: 30755417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.